Kruscha / Pixabay

French biopharma company NFL Biosciences has raised €5m following its IPO at Euronext Growth Paris.

With a €20m financing round under its belt, Promethera Therapeutics is poised to start its Phase IIb study for its stem cell therapy treating liver failure.

© Pixabay.com

Early-stage venture capital investor Novalis Biotech has closed its Biotech Acceleration Fund at €25m to drive growth of translational medicine start-ups.

© Discover Echo Inc.

Swedish Cellink AB has announced a bid of $110m to take over all shares of Discover Echo Inc., 11% of which to be paid in newly issued shares.

© RheinCell Therapeutics GmbH

Major CDMO Catalent has swallowed German RheinCell Therapeutics GmbH, an iPSC specialist, to expand its offerings in cell and gene therapies.

Face2Gene applications. © FDNA

In an effort to ban AI tools for facial recognition, the EU risks to block European medical geneticists to recognise genetic diseases.

BBB © NIH, Kristin Johnson/Vascular Biology Program, Boston Children's Hospital

NeuVasQ Biotechnologies has raised €20m through a Series A investment to advance its technology platform that restores the integrity of the blood-brain barrier in acute neurological disorders.

© Coriolis Pharma

Coriolis Pharma will launch operations at its currently expanded ATMP development facilities by Q4/2021.

Picture: chfonk/freepik

Company seeks new opportunities for use of mRNA therapeutics.

Picture: user7350813/freepik

U.S. government to purchase at not-for-profit price 200 million doses in 2021 and 300 million in the first half of 2022.